Narzędzia help

Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
next last
cannonical link button

http://yadda.icm.edu.pl:443/baztech/element/bwmeta1.element.baztech-1aa687a9-abe2-4a93-a525-83ddcda44c85

Czasopismo

Biocybernetics and Biomedical Engineering

Tytuł artykułu

Treatment of patients with type 1 diabetes – Insulin pumps or multiple injections?

Autorzy Krzymien, J.  Rachuta, M.  Kozlowska, I.  Ladyzynski, P.  Foltynski, P. 
Treść / Zawartość http://www.ibib.waw.pl/pl/wydawnictwa/biocybernetics-and-biomedical-enginering-bbe/bbe-tomy http://www.journals.elsevier.com/biocybernetics-and-biomedical-engineering/
Warianty tytułu
Języki publikacji EN
Abstrakty
EN In theory, the continuous subcutaneous insulin infusion (CSII) has a few advantages over the multiple daily insulin injections (MDI) that should lead to improved glycemic control and lower risk of hypoglycemia. In practice, both treatment regimens allow for adequate control of glycemia. The objective of this review is to discuss the most important factors contributing to this situation. We made a comprehensive evidence-based review of the factors affecting effectiveness of CSII and MDI, with a special attention to algorithms for insulin dose adjustments and the automatic bolus calculators. Regardless of the treatment regimen that is used a few different interdependent factors influence the final result of the intensive insulin therapy. These factors comprise: patients' education, attitude, emotional stability and compliance, and careful analysis of the treatment results by a physician establishing the appropriate rate of basal insulin infusion or the basal dose of insulin and adjusting insulin doses to: the meals, the planned physical activity and the actual and target glucose levels. Our study implies that good glycemic control in patients with type 1 diabetes requires not only a thorough patient education and complying with medical recommendations, but also an individual determination of therapy goals and ways of achieving them. That is why, regardless of the treatment method that is applied, it is the choice of appropriate algorithms and adjusting them to the patient's way of life what allow for achieving pre-specified therapeutic goals. Technical means such as automatic bolus calculators might supplement but they cannot replace patients education and compliance.
Słowa kluczowe
PL cukrzyca   cukrzyca typu 1   infuzja   zastrzyk insulinowy  
EN diabetes mellitus   type 1 diabetes   continuous subcutaneous insulin   infusion   multiple daily insulin injections   automatic bolus calculator  
Wydawca Nałęcz Institute of Biocybernetics and Biomedical Engineering of the Polish Academy of Sciences
Elsevier
Czasopismo Biocybernetics and Biomedical Engineering
Rocznik 2016
Tom Vol. 36, no. 1
Strony 1--8
Opis fizyczny Bibliogr. 60 poz., tab., wykr.
Twórcy
autor Krzymien, J.
autor Rachuta, M.
  • Clinic of Gastroenterology and Metabolic Diseases, Medical University of Warsaw, Warsaw, Poland, m.rachuta@op.pl
autor Kozlowska, I.
  • Clinic of Gastroenterology and Metabolic Diseases, Medical University of Warsaw, Warsaw, Poland, iko2@interia.pl
autor Ladyzynski, P.
  • Nalecz Institute of Biocybernetics and Biomedical Engineering Polish Academy of Sciences, 4 Trojdena Street, 02-109 Warsaw, Poland, pladyzynski@ibib.waw.pl
autor Foltynski, P.
  • Nalecz Institute of Biocybernetics and Biomedical Engineering Polish Academy of Sciences, 4 Trojdena Street, 02-109 Warsaw, Poland, pfoltynski@ibib.waw.pl
Bibliografia
[1] The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86.
[2] American Diabetes Association. Standards of medical care in diabetes – 2015 abridged for primary care providers. Clin Diabetes 2015;33:97–111.
[3] American Diabetes Association. Advantages of using an insulin pump; 2013, http://www.diabetes.org/living-with-diabetes/ treatment-and-care/medication/insulin/ advantages-of-using-an-insulin-pump.html [accessed 20.05.15].
[4] Shaltin S, Phillip M. Hypoglycemia in type 1 diabetes. Diabetes Care 2008;31(Suppl. 2):121–4.
[5] Yeh H-C, Brown TT, Maruthur N, Ranasinghe P, Beerger Z, Suh YD, et al. Comparative effectiveness and safety methods of insulin delivery and glucose monitoring of diabetes mellitus. Ann Intern Med 2012;157:336–47.
[6] Wiessenberg-Benchell J, Antisdel Lomaglio J, Seshader R. Insulin pump therapy. Diabetes Care 2003;26:1079–87.
[7] DeVries JH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care 2002;25:2074–80.
[8] Bolli GB, Kerr D, Thomas R, Torlone E, Sola-Gozagnes A, Vitacolonna E, et al. Comparison of multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes. Diabetes Care 2009;32:1170–6.
[9] Bergenstal RM, Tamborlane WV, Ahmann A, Dailey G, Davis SN, Joyce CJ, et al. Sensor-augmented pump therapy for A1c reduction (STAR 3) study. Diabetes Care 2011;34:2403–5.
[10] Choudhary P, Shin J, Wang Y, Evans M, Hammond PJ, Kerr D, et al. Insulin pump therapy with automated insulin suspension in response to hypoglycemia. Diabetes Care 2011;34:2023–5.
[11] American Diabetes Association. Standards of medical care in diabetes – 2014. Diabetes Care 2014;37(Suppl. 1):S14–80.
[12] Polish Diabetes Society. Clinical recommendations for treatment of patients with diabetes 2014. Diabetol Klin 2014;3(Suppl. A) [in Polish].
[13] Krzymien J, Piksa E, Bonalska B, Karnafel W. Knowledge about carbohydrate exchange in persons with long-term, ill-controlled, type 1 diabetes. XIV Meeting of the Polish Diabetes Society; 2013 [Abstract book P45, in Polish].
[14] Brazeau AS, Mircescu H, Desjardins K, Leroux C, Strychar I, Ekoé JM, et al. Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes. Diabetes Res Clin Pract 2013;99(1):19–23.
[15] Spiegel G, Bortsov A, Bishop FK, Owen D, Klingensmith GJ, Mayer-Davis EJ, et al. Randomized nutrition education intervention to improve carbohydrate counting in adolescents with type 1 diabetes study: is more intensive education needed? J Acad Nutr Diet 2012;112(11):1736–46.
[16] Puri M, Zhu Z, Yu Q, Divakaran A, Sawhney H. Recognition and volume estimation of food intake using a mobile device. Proc. Workshop Appl. Comput. Vis.. 2009. pp. 1–8.
[17] Pouladzadeh P, Villalobos G, Almaghrabi R, Shirmohammadi S. A novel SVM based food recognition method for calorie measurement applications. IEEE Intern. Conf. Multimedia and Expo Workshops. 2012. pp. 495–8.
[18] Foltynski P, Ladyzynski P, Wojcicki JM, Pankowska E, Migalska-Musial K, Krzymien J. System for calculating of compensating insulin dose from voice description of meal. In: Lackovic I, Vasica D, editors. 6th Eur Conf IFMBE (MBEC 2014) IFMBE Proc, vol. 45. 2015. p. 728–31.
[19] Foltynski P, Ladyzynski P, Pankowska E, Mazurczak K, Migalska-Musial K. An algorithm based on voice description of meal for insulin dose calculation to compensate food intake. In: Jaffray DA, editor. World Congress Med Phys Biomed Eng (WC 2015) IFMBE Proc, vol. 51. 2015. p. 1441–4.
[20] Pasler S, Wolff M, Fischer WJ. Food intake monitoring: an acoustical approach to automated food intake activity detection and classification of consumed food. Physiol Meas 2012;33(6):1073–93.
[21] Sazonov E, Schuckers S, Lopez-Meyer P, Makeyev O, Sazonova N, Melanson EL, et al. Non-invasive monitoring of chewing and swallowing for objective quantification of ingestive behavior. Physiol Meas 2008;29:525–41.
[22] Ladyzynski P, Wojcicki JM, Jozwicka E, Blachowicz J, Krzymień J. Reliability of blood glucose self-monitoring and its influence on glycemic control in highly motivated type 1 diabetic patients. Diabetes Care 1999;22:854–6.
[23] Vanderwel BW, Messer LH, Horton LA, McNair B, Cobry EC, McFann KK, et al. Missed insulin boluses for snacks in youth with type 1 diabetes. Diabetes Care 2010;33:507–8.
[24] Connel MA, Gilbertson HR, Doaneth SM, Cameron FJ. Optimazing postprandial glycemia in pediatric patients with type 1 diabetes using insulin pump therapy. Diabetic Care 2008;31:1491–5.
[25] Walsh J, Roberts R, Bailey T. Guidelines for insulin dosing in continuous subcutaneous insulin infusion using new formulas from a retrospective study of individuals with optimal glucose levels. J Diabetes Sci Technol 2010;4: 1174–81.
[26] Walsh J, Roberts R, Bailey T. Guidelines for optimal bolus calculator settings in adults. J Diabetes Sci Technol 2011;5:129–35.
[27] Krzymien J, Krynska L. Eating disorders in patients with diabetes. Przew Lek 2005;3:32–5.
[28] Krzymien J, Karnafel W. Lactic acidosis in patients with diabetes. Pol Arch Med Wewn 2013;123:91–7.
[29] King AB. How much do I give? Reevaluation of insulin dosing estimation formulas using continuous glucose monitoring. Endocr Pract 2010;16:428–32.
[30] Krzymien J, Szymerska E, Tracz M, Regulski M, Jasik M. An influence of the insulin sensitivity on prevalence of the early-morning hyperglycemia in patients with diabetes treated with insulin. Pol Arch Med Wewn 1989;81:176–82 [in Polish].
[31] Heinemann L, Nosek L, Kapitza C, Schweitzer MA, Krinelke L. Changes in basal insulin infusion rates with subcutaneous insulin infusion: time until a change in metabolic effect is induced in patients with type 1 diabetes. Diabetes Care 2009;32:1437–9.
[32] Lepore M, Pampanelli S, Fanelli. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142–8.
[33] Porcellati F, Rossetti P, Ricci NB, Pampanelli S, Torlone E, Campos SH, et al. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. Diabetes Care 2007;30:2447–52.
[34] Poon K, King AB. Glargine and detemir: safety and efficacy profiles of the long-acting basal insulin analogs. Drug Health Patient Saf 2010;2:213–23.
[35] Zisser H, Wagner R, Pleus S, Haug C, Jendrike N, Parkin C, et al. Clinical performance of three bolus calculators in subjects with type 1 diabetes mellitus: a head-to-head-to-head comparison. Diabetes Technol Ther 2010;12:955–61.
[36] Shwide-Slavin C. Case study: a patient with type 1 diabetes who transitions to insulin pump therapy by working with an advanced practice dietitian. Diabetes Spectr 2003;16:37–40.
[37] Davidson PC, Hebblewhite HR, Bode BW, Steed RD, Welch NS, Greenlee MC, et al. Statistically based CSII parameters: correction factor (CF) (1700 rule), carbohydrate-insulin ratio(CIR) (2.8 rule), and basal-to-total ratio. Diabetes Technol Ther 2003;5:237.
[38] Kuroda A, Kaneto H, Yasuda T, Matsuhisa M, Mmiyashita K, Fujik N, et al. Basal insulin requirement is _30% of the total daily insulin dose in type 1 diabetic patients who use the insulin pump. Diabetes Care 2011;34:1089–90.
[39] Davidson PC, Hebblewhite HR, Steed RD, Bode BW. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio. Endocr Pract 2008;14:1095–101.
[40] Pankowska E, Blazik M. Bolus calculator with nutrition database software, a new concept of prandial insulin programming for pump users. J Diabetes Sci Technol 2010;4:571–6.
[41] Gawrecki A, Duda-Sobczak A, Zozulinska-Ziolkiewicz D, Wierusz-Wysocka B. Selected aspects of insulin pump therapy in adults with type 1 diabetes. Diabetol Prakt 2011;12:128–33.
[42] Basu A, Dalla Man C, Basu R, Toffolo G, Cobelli C, Rizza RA. Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism. Diabetes Care 2009;32:866–72.
[43] Mader JK, Birngruber T, Korsatko S, Deller S, Köhler G, Boysen S, et al. Enhanced absorption of insulin aspart as the result of a dispersed injection strategy tested in a randomized trial in type 1 diabetic patients. Diabetes Care 2013;36:780–5.
[44] Fabbrini E, Higgins PB, Magkos F, Bastarrachea RA, Voruganti VS, Comuzzie AG, et al. Metabolic response to high-carbohydrate and low-carbohydrate meals in a nonhuman primate model. Am J Physiol Endocrinol Metab 2013;304:444–51.
[45] Bangstad H-J, Danne T, Deeb LC, Jarosz-Chobot P, Urakami T, Hanas R. Insulin treatment. Pediatr Diabetes 2007;8:88– 102.
[46] Colin IM, Paris I. Glucose meters with built-in automated bolus calculator: gadget or real value for insulin-treated diabetic patients? Diabetes Ther 2013;4:1–11.
[47] Schrezenmeir J, Dirting K, Papazov P. Controlled multicenter study on the effect of computer assistance in intensive insulin therapy of type 1 diabetics. Comput Methods Programs Biomed 2002;69:97–114.
[48] Gross TM, Kayne D, King A, Rother C, Juth S. A bolus calculator is an effective means of controlling postprandial glycemia in patients on insulin pump therapy. Diabetes Technol Ther 2003;5:365–9.
[49] Glaser NS, Iden SB, Green-Burgeson D, Bennett C, Hood- Johnson K, Styne DM, et al. Benefits of an insulin dosage calculation device for adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2004;17:1641–51.
[50] Garg SK, Bookout TR, McFann KK, Kelly WC, Beatson C, Ellis SL, et al. Improved glycemic control in intensively treated adult subjects with type 1 diabetes using insulin guidance software. Diabetes Technol Ther 2008;10:369–75.
[51] Klupa T, Benbenek-Klupa T, Malecki M, Szalecki M, Sieradzki J. Clinical usefulness of a bolus calculator in maintaining normo-glycaemia in active professional patients with type 1 diabetes treated with continuous subcutaneous insulin infusion. J Int Med Res 2008;36:1112–6.
[52] Shashaj B, Busetto E, Sulli N. Benefits of a bolus calculator in pre- and postprandial glycemic control and meal flexibility of paediatric patients using continuous subcutaneous insulin infusion (CSII). Diabet Med 2008;25:1036–42.
[53] Ahola AJ, Mäkimattila S, Saraheimo M, Mikkilä V, Forsblom C, Freese R, et al. Many patients with type 1 diabetes estimate their prandial insulin need inappropriately. J Diabetes 2010;2:194–202.
[54] Maurizi AR, Lauria A, Maggi D, Palermo A, Fioriti E, Manfrini S, et al. A novel insulin unit calculator for the management of type 1 diabetes. Diabetes Technol Ther 2011;13:425–8.
[55] Blazik M, Pankowska E. The effect of bolus and food calculator diabetics on glucose variability in children with type 1 diabetes treated with insulin pump: the results of RCT. Pediatr Diabetes 2012;13:534–9.
[56] Enander R, Gundevall C, Strömgren A, Chaplin J, Hanas R. Carbohydrate counting with a bolus calculator improves post-prandial blood glucose levels in children and adolescents with type 1 diabetes using insulin pumps. Pediatr Diabetes 2012;13:545–51.
[57] Lepore G, Dodesini AR, Nosari I, Scaranna C, Corsi A, Trevisan R. Bolus calculator improves long-term metabolic control and reduces glucose variability in pump-treated patients with type 1 diabetes. Nutr Metab Cardiovasc Dis 2012;22:e15–6.
[58] Schmidt S, Meldgaard M, Serifovski N, Storm C, Christensen TM, Gade-Rasmussen B, et al. Use of an automated bolus calculator in MDI-treated type 1 diabetes: the BolusCal Study, a randomized controlled pilot study. Diabetes Care 2012;35:984–90.
[59] Sussman A, Taylor EJ, Patel M, Ward J, Alva S, Lawrence A, et al. Performance of a glucose meter with a built-in automated bolus calculator versus manual bolus calculation in insulin-using subjects. J Diabetes Sci Technol 2012;6:339–44.
[60] Barnard K, Parkin C, Young A, Ashraf M. Use of an automated bolus calculator reduces fear of hypoglycemia and improves confidence in dosage accuracy in patients with type 1 diabetes mellitus treated with multiple daily insulin injections. J Diabetes Sci Technol 2012;6:144–9.
Uwagi
PL Opracowanie ze środków MNiSW w ramach umowy 812/P-DUN/2016 na działalność upowszechniającą naukę.
Kolekcja BazTech
Identyfikator YADDA bwmeta1.element.baztech-1aa687a9-abe2-4a93-a525-83ddcda44c85
Identyfikatory
DOI 10.1016/j.bbe.2015.10.002